Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ropinirole' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 76 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Waters, CH
      Advances in managing Parkinson's disease

      HOSPITAL PRACTICE
    2. Zenzola, A; Diroma, C; Fraddosio, A; Lamberti, S; Moramarco, A; Palagano, G; Iliceto, G
      Efficacy and tolerability of dopamine agonists in a parkinsonian population

      NEUROLOGICAL SCIENCES
    3. Sanjiv, CC; Schulzer, M; Mak, E; Fleming, J; Martin, WRW; Brown, T; Calne, SM; Tsui, J; Stoessl, AJ; Lee, CS; Calne, DB
      Daytime somnolence in patients with Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    4. Weimerskirch, PR; Ernst, ME
      Newer dopamine agonists in the treatment of restless legs syndrome

      ANNALS OF PHARMACOTHERAPY
    5. Bair, JD; Oppelt, TF
      Warfarin and ropinirole interaction

      ANNALS OF PHARMACOTHERAPY
    6. Armer, JA; Martin, WRW; Pogarell, O
      Tolerability and safety profile of pramipexole in the treatment of Parkinson's disease

      REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
    7. Zafonte, RD; Lexell, J; Cullen, N
      Possible applications for dopaminergic agents following traumatic brain injury: Part 2

      JOURNAL OF HEAD TRAUMA REHABILITATION
    8. Saletu, M; Anderer, P; Saletu, B; Hauer, C; Mandl, M; Semler, B; Saletu-Zyhlarz, G
      Sleep laboratory studies in periodic limb movement disorder (PLMD) patients as compared with normals and acute effects of ropinirole

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    9. Maratos, EC; Jackson, MJ; Pearce, RKB; Jenner, P
      Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)

      MOVEMENT DISORDERS
    10. Tanaka, K; Miyazaki, I; Fujita, N; Haque, ME; Asanuma, M; Ogawa, N
      Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist

      NEUROCHEMICAL RESEARCH
    11. Gimenez-Roldan, S; Esteban, EM; Mateo, D
      Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: Open label pilot responses to three different dose-ratios

      CLINICAL NEUROPHARMACOLOGY
    12. Jankovic, J; Tan, EK
      Choosing dopamine agonists in Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    13. Montastruc, JL; Brefel-Courbon, C; Senard, JM; Bagheri, H; Ferreira, J; Rascol, O; Lapeyre-Mestre, M
      Sleep attacks and antiparkinsonian drugs: A pilot prospective pharmacoepidemiologic study

      CLINICAL NEUROPHARMACOLOGY
    14. Micallef-Roll, J; Rihet, P; Hasbroucq, T; Possamai, C; Blin, O
      Levodopa-induced drowsiness in healthy volunteers: Results of a choice reaction time test combined with a subjective evaluation of sedation

      CLINICAL NEUROPHARMACOLOGY
    15. Mungersdorf, M; Sommer, U; Sommer, M; Reichmann, H
      High-dose therapy with ropinirole in patients with Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    16. Hanna, PA; Ratkos, L; Ondo, WG; Jankovic, J
      Switching from pergolide to pramipexole in patients with Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    17. Tuite, P; Ebbitt, B
      Dopamine agonists

      SEMINARS IN NEUROLOGY
    18. Etminan, M; Samii, A; Takkouche, B; Rochon, PA
      Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease - A meta-analysis of randomised controlled trials

      DRUG SAFETY
    19. Rascol, O; Ferreira, J; Montastruc, JL
      Abnormal daytime somnolence, "sleep attacks", and antiparkinson drugs

      REVUE NEUROLOGIQUE
    20. Lees, AJ; Katzenschlager, R; Head, J; Ben-Shlomo, Y
      Ten-year follow-up of three different initial treatments in de-novo PD - Arandomized trial

      NEUROLOGY
    21. Lledo, A
      Dopamine agonists: the treatment for Parkinson's disease in the XXI century?

      PARKINSONISM & RELATED DISORDERS
    22. Ferreira, JJ; Rascol, O
      Drug-related sleep disturbances and Parkinson's disease: effects of dopaminergic antiparkinsonian drugs on sleep and wakefulness

      EUROPEAN JOURNAL OF NEUROLOGY
    23. Young, LR; Justice, LN
      Parkinson's disease: Focus on management alternatives

      AMERICAN JOURNAL OF MANAGED CARE
    24. Rye, DB; Bliwise, DL; Dihenia, B; Gurecki, P
      Daytime sleepiness in Parkinson's disease

      JOURNAL OF SLEEP RESEARCH
    25. Hauser, RA; Gauger, L; Anderson, WM; Zesiewicz, TA
      Pramipexole-induced somnolence and episodes of daytime sleep

      MOVEMENT DISORDERS
    26. Gerlach, M; Riederer, P; Reichmann, H
      Preclinical and clinical aspects of dopamine agonists. What is known for certain?

      NERVENHEILKUNDE
    27. Baas, H
      Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors

      JOURNAL OF NEUROLOGY
    28. Schafer, D; Greulich, W
      Effects of parkinsonian medication on sleep

      JOURNAL OF NEUROLOGY
    29. Lachenmayer, L
      Parkinson's disease and the ability to drive

      JOURNAL OF NEUROLOGY
    30. Saletu, B; Gruber, G; Saletu, M; Brandstatter, N; Hauer, C; Prause, W; Ritter, K; Saletu-Zyhlarz, G
      Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole 1. Findings on objective and subjective sleep and awakening quality

      NEUROPSYCHOBIOLOGY
    31. Saletu, M; Anderer, P; Saletu, B; Hauer, C; Mandl, M; Oberndorfer, S; Zoghlami, A; Saletu-Zyhlarz, G
      Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole 2. Findings on periodic leg movement, arousals and respiratory variables

      NEUROPSYCHOBIOLOGY
    32. Lam, YWF
      Clinical pharmacology of dopamine agonists

      PHARMACOTHERAPY
    33. LeWitt, PA
      New drugs for the treatment of Parkinson's disease

      PHARMACOTHERAPY
    34. Pirker, W; Happe, S
      Sleep attacks in Parkinson's disease

      LANCET
    35. Tanner, CM
      Dopamine agonists in early therapy for Parkinson disease - Promise and problems

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    36. Fukuzaki, K; Kamenosono, T; Kitazumi, K; Nagata, R
      Effects of ropinirole on motor behavior in MPTP-treated common marmosets

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    37. Fukuzaki, K; Kamenosono, T; Nagata, R
      Effects of ropinirole on various Parkinsonian models in mice, rats, and cynomolgus monkeys

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    38. Broussolle, E
      Dopa-therapy in the treatment of early stage Parkinson's disease

      REVUE NEUROLOGIQUE
    39. Rascol, O; Montastruc, JL
      Role of dopaminergic agonists

      REVUE NEUROLOGIQUE
    40. Marion, MH
      Drug treatments and motor complications in advanced stage Parkinson's disease

      REVUE NEUROLOGIQUE
    41. Moller, JC; Stiasny, K; Cassel, W; Peter, JH; Kruger, HP; Oertel, WH
      "Sleep attacks" in parkinsonian patients: a side effect of nonergoline dopamine agonists or a class effect of dopamimetic agents?

      NERVENARZT
    42. Riechmann, H; Lachenmayer, L
      The first double-blinded long-term study of the effectivity and dyskinesiaprophylaxis of ropinirole

      NERVENARZT
    43. Brooks, DJ
      Dopamine agonists: their role in the treatment of Parkinson's disease

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    44. Matheson, AJ; Spencer, CM
      Ropinirole - A review of its use in the management of Parkinson's disease

      DRUGS
    45. Tan, EK; Ondo, W
      Clinical characteristics of pramipexole-induced peripheral edema

      ARCHIVES OF NEUROLOGY
    46. Rogers, DC; Costall, B; Domeney, AM; Gerrard, PA; Greener, M; Kelly, ME; Hagan, JJ; Hunter, AJ
      Anxiolytic profile of ropinirole in the rat, mouse and common marmoset

      PSYCHOPHARMACOLOGY
    47. Coufal, P; Stulik, K; Claessens, HA; Hardy, MJ; Webb, M
      Separation and quantification of ropinirole and some impurities using capillary liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    48. Poewe, W
      Recent advances in the drug treatment of Parkinson's disease

      CURRENT OPINION IN NEUROLOGY
    49. Kuzel, MD
      Ropinirole: A dopamine agonist for the treatment of Parkinson's disease

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    50. Montastruc, JL; Rascol, O; Senard, JM
      Treatment of Parkinson's disease should begin with a dopamine agonist

      MOVEMENT DISORDERS
    51. Ondo, W
      Ropinirole for restless legs syndrome

      MOVEMENT DISORDERS
    52. Ceballos-Baumann, AO
      New aspects in the treatment of Parkinson's disease

      NERVENHEILKUNDE
    53. Taylor, A; Beerahee, A; Citerone, D; Davy, M; Fitzpatrick, K; Lopez-Gil, A; Stocchi, F
      The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    54. Rascol, O
      Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?

      JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT
    55. Canesi, M; Antonini, A; Mariani, CB; Tesei, S; Zecchinelli, AL; Barichella, M; Pezzoli, G
      An overnight switch to ropinirole therapy in patients with Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    56. Ludin, HP
      Current treatment modalities for Parkinson's disease

      SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT
    57. Thalamas, C; Taylor, A; Brefel-Courbon, C; Eagle, S; Fitzpatrick, K; Rascol, O
      Lack of pharmacokinetic interaction between ropinirole and theophylline inpatients with Parkinson's disease

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    58. Arnold, G; Kupsch, A
      High dose therapy of a patient with Parkinson's disease with the novel dopamine agonist Pramipexole allows reduction of L-dopa down to nil

      NERVENARZT
    59. Perachon, S; Schwartz, JC; Sokoloff, P
      Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2 and D-3 receptors

      EUROPEAN JOURNAL OF PHARMACOLOGY
    60. Coldwell, MC; Boyfield, I; Brown, T; Hagen, JJ; Middlemiss, DN
      Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D-2(long), D-3 and D-4.4 receptors expressed in Chinese hamster ovary cells

      BRITISH JOURNAL OF PHARMACOLOGY
    61. Coufal, P; Stulik, K; Claessens, HA; Hardy, MJ; Webb, M
      Determination of the dissociation constants of ropinirole and some impurities and their quantification using capillary zone electrophoresis

      JOURNAL OF CHROMATOGRAPHY B
    62. SWERDLOW NR; TAAID N; OOSTWEGEL JL; RANDOLPH E; GEYER MA
      TOWARDS A CROSS-SPECIES PHARMACOLOGY OF SENSORIMOTOR GATING - EFFECTSOF AMANTADINE, BROMOCRIPTINE, PERGOLIDE AND ROPINIROLE ON PREPULSE INHIBITION OF ACOUSTIC STARTLE IN RATS

      Behavioural pharmacology
    63. PEARCE RKB; BANERJI T; JENNER P; MARSDEN CD
      DE-NOVO ADMINISTRATION OF ROPINIROLE AND BROMOCRIPTINE INDUCES LESS DYSKINESIA THAN L-DOPA IN THE MPTP-TREATED MARMOSET

      Movement disorders
    64. POEWE WH; RASCOL O; BROOKS DJ; BRUNT ER; KORCZYN AD; STOCCHI F
      ROPINIROLE IN THE TREATMENT OF EARLY PARKINSONS-DISEASE - A 6-MONTH INTERIM-REPORT OF A 5-YEAR LEVODOPA-CONTROLLED STUDY

      Movement disorders
    65. KORCZYN AD; BROOKS DJ; BRUNT ER; POEWE WH; RASCOL O; STOCCHI F
      ROPINIROLE VERSUS BROMOCRIPTINE IN THE TREATMENT OF EARLY PARKINSONS-DISEASE - A 6-MONTH INTERIM-REPORT OF A 3-YEAR STUDY

      Movement disorders
    66. SCHRAG AE; BROOKS DJ; BRUNT E; FUELL D; KORCZYN A; POEWE W; QUINN NP; RASCOL O; STOCCHI F
      THE SAFETY OF ROPINIROLE, A SELECTIVE NONERGOLINE DOPAMINE AGONIST, IN PATIENTS WITH PARKINSONS-DISEASE

      Clinical neuropharmacology
    67. BROOKS DJ; ABBOTT RJ; LEES AJ; MARTIGNONI E; PHILCOX DV; RASCOL O; ROOS RAC; SAGAR HJ
      A PLACEBO-CONTROLLED EVALUATION OF ROPINIROLE, A NOVEL D-2 AGONIST, AS SOLE DOPAMINERGIC THERAPY IN PARKINSONS-DISEASE

      Clinical neuropharmacology
    68. BREFEL C; THALAMAS C; RAYET S; LOPEZGIL A; FITZPATRICK K; BULLMAN S; CITERONE DR; TAYLOR AC; MONTASTRUC JL; RASCOL O
      EFFECT OF FOOD ON THE PHARMACOKINETICS OF ROPINIROLE IN PARKINSONIAN-PATIENTS

      British journal of clinical pharmacology
    69. HAMILTON GS
      EMERGING THERAPEUTIC AGENTS FOR PARKINSONS-DISEASE

      Chemistry and Industry
    70. GOTTWALD MD; BAINBRIDGE JL; DOWLING GA; AMINOFF MJ; ALLDREDGE BK
      NEW PHARMACOTHERAPY FOR PARKINSONS-DISEASE

      The Annals of pharmacotherapy
    71. LEWITT PA
      NEW OPTIONS FOR TREATMENT OF PARKINSONS-DISEASE

      Bailliere's clinical neurology
    72. BARBATO L; STOCCHI F; MONGE A; VACCA L; RUGGIERI S; NORDERA G; MARSDEN CD
      THE LONG-DURATION ACTION OF LEVODOPA MAY BE DUE TO A POSTSYNAPTIC EFFECT

      Clinical neuropharmacology
    73. HAGAN JJ; MIDDLEMISS DN; SHARPE PC; POSTE GH
      PARKINSONS-DISEASE - PROSPECTS FOR IMPROVED DRUG-THERAPY

      Trends in pharmacological sciences
    74. RASCOL O; LEES AJ; SENARD JM; PIRTOSEK Z; MONTASTRUC JL; FUELL D
      ROPINIROLE IN THE TREATMENT OF LEVODOPA-INDUCED MOTOR FLUCTUATIONS INPATIENTS WITH PARKINSONS-DISEASE

      Clinical neuropharmacology
    75. PICCOLI F; RIUGGERI RM
      DOPAMINERGIC AGONISTS IN THE TREATMENT OF PARKINSONS-DISEASE - A REVIEW

      Journal of neural transmission. Supplementum
    76. PARKER SG; RAVAL P; YEULET S; EDEN RJ
      TOLERANCE TO PERIPHERAL, BUT NOT CENTRAL, EFFECTS OF ROPINIROLE, A SELECTIVE DOPAMINE D-2-LIKE RECEPTOR AGONIST

      European journal of pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/08/20 alle ore 01:29:07